MedTrace Logo

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

NCT04184258 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2021-01-22

No results posted yet for this study

Summary

Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

Conditions

Interventions

BIOLOGICAL

Pooled mesenchymal stem cell

Pooled allogenic mesenchymal stem cell derived from olfactory mucosa

OTHER

Standard treatment according to the Clinical protocols

Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus

Sponsors & Collaborators

  • Belarusian State Medical University

    collaborator OTHER

  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

    lead OTHER_GOV

Principal Investigators

  • Andrei Hancharou, Dr · Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

  • Konstantin A Chizh, Dr · Associate professor, Belarusian State Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Belarus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04184258 on ClinicalTrials.gov